Clinical Trial

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 4, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-17; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2025-02-21
Trial Details
NCT Number NCT06514612
Lead Sponsor Santen SAS
Conditions Acquired Blepharophimosis
Enrollment 234 participants
Start Date 2024-12-30
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-04